COPPER-ATOM IDENTIFICATION IN THE DIFFERENT ACTIVE AND INACTIVE FORMS OF RECOMBINANT FACTOR-VIII-DELTA-II AND PLASMA-DERIVED FACTOR-VIII

被引：0
|
作者：
BIHOREAU, N
RAMON, C
PIN, S
FONTAINEAUPART, MP
机构：
[1] LAB FRANCAIS FRACTIONNEMENT & BIOTECHNOL,LES ULIS,FRANCE
[2] UNIV PARIS 11,PHOTOPHYS MOLEC LAB,F-91405 ORSAY,FRANCE
[3] UNIV DENIS DIDEROT,BIOL PHYSICOCHIM LAB,PARIS,FRANCE
来源：
THROMBOSIS AND HAEMOSTASIS | 1995年 / 73卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1215 / 1215
页数：1
相关论文
共 50 条
  • [21] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIIA DO NOT CORRECT BLEEDING-TIME IN A RABBIT FACTOR-VIII INHIBITOR MODEL
    TURECEK, PL
    SCHWARZ, HP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 986 - 986
  • [22] COMPARISON OF RECOMBINANT FACTOR-VIII, FACTOR VIII-DELTA-II, PRODUCED BY CHO CELLS WITH OR WITHOUT FETAL CALF SERUM
    PAOLANTONACCI, P
    BIHOREAU, N
    SAUGER, A
    MIGNOT, G
    KERAVEC, J
    ROMETLEMONNE, JL
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1161 - 1161
  • [23] Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review
    Iorio, A.
    Halimeh, S.
    Goldenberg, N.
    Kenet, G.
    Young, G.
    Brandao, L.
    HAEMOPHILIA, 2010, 16 : 74 - 74
  • [24] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [25] FACTOR-VIII INHIBITOR ASSAYS USING PLASMA-DERIVED FVIII VERSUS RECOMBINANT FVIII - A COMPARATIVE-STUDY
    HILLMANWISEMAN, C
    VITALE, C
    LUSHER, J
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 684 - 684
  • [26] TRANSMISSION OF HUMAN PARVOVIRUS B19 BY PLASMA-DERIVED FACTOR-VIII CONCENTRATES
    LAURIAN, Y
    DUSSAIX, E
    PARQUET, A
    CHALVONDEMERSAY, A
    DOIRON, R
    TCHERNIA, G
    NOUVELLE REVUE FRANCAISE D HEMATOLOGIE, 1994, 36 (06): : 449 - 453
  • [27] Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)
    Prezotti, A.
    Montalvao, S.
    Marques, A.
    Ferreira, C.
    Oliveira, L.
    Villaca, P.
    Ferreira Filho, L.
    Lorenzato, C.
    Medina, S.
    Araujo, F.
    Ozelo, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 366 - 366
  • [28] Pharmacokinetics of recombinant and plasma-derived factor VIII products in paediatric patients with severe haemophilia A
    Steele, M. R.
    Nagel, K.
    Chan, A. K. C.
    HAEMOPHILIA, 2014, 20 (01) : E100 - E101
  • [29] Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review
    Iorio, A.
    Halimeh, S.
    Bidlingmaier, C.
    Ettingshausen, C. E.
    Gringeri, A.
    Holzhauer, S.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 (02) : 410 - 410
  • [30] THE PHARMACOKINETICS AND VIRAL SAFETY OF A NEW PLASMA-DERIVED FACTOR-VIII CONCENTRATE, KOATE-HP
    ROUSELL, RH
    ABILDGAARD, CF
    BROCKWAY, WJ
    DOBKIN, MB
    HARRISON, J
    HEIN, R
    PAPPENHAGEN, AR
    SANCHEZ, LH
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 211 - 211
12345